Protalix BioTherapeutics

PLXNYSE Israel Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$198.206 M

$2.46 +0.82%

Close of 7 Aug 2026

Revenue

$52.7M

#2726 by revenue

Earnings

-$6.60M

Loss-making

Shares outstanding

80,571,642

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#93CompugenCGEN$227.9M
#94InvivydIVVD$218.0M
#95Protalix BioTherapeuticsPLX$198.2M
#96AlectorALEC$197.6M
#97Voyager TherapeuticsVYGR$197.6M

Where these numbers come from

Share counts and financials for Protalix BioTherapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.